Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic

References

• McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005;11:S286–95; quiz S307-11.
   PubMed Web of Science ®Google Scholar
• Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009;49:561–73.
   PubMed Web of Science ®Google Scholar
• Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol 2003;38:864–70.
   PubMed Web of Science ®Google Scholar
• Kristiansen MG, Gutteberg T, Berg LK, Sjursen H, Mortensen L, Florholmen J. [Hepatitis C in Northern Norway–an 8-year material]. Tidsskr Nor Laegeforen 2002;122:1974–6.
   PubMedGoogle Scholar
• Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;345:211–15.
   PubMed Web of Science ®Google Scholar
• Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 2013;57:S105–10.
   PubMed Web of Science ®Google Scholar
• Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013;57:S129–37.
   PubMed Web of Science ®Google Scholar
• Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol 2012; Epub 2012/09/11; doi: 10.1016/j.jhep.2012.08.024; PubMed PMID: 22960427.
   PubMedGoogle Scholar
• Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int 2013;33:30–4.
   PubMed Web of Science ®Google Scholar
• Bergstrøm K, Fischler B, Bylund P, Gerdén B, Duberg A, Josephson F, et al. Läkemedelsbehandling av kronisk hepatit C hos vuxna och barn - uppdaterad rekommendation. Inf Från Läkemedelsverket 2008;19:14–27.
   Google Scholar
• Dalgard O, Egeland A, Ervik R, Vilimas K, Skaug K, Steen TW. [Risk factors for hepatitis C among injecting drug users in Oslo]. Tidsskr Nor Laegeforen 2009;129:101–4.
   PubMedGoogle Scholar
• Rastad J, Albert J, Andersson J, Beerman B, Wiechel A, Braconier J, et al. Behandling av kronisk hepatit C hos vuxna och barn. Inf Från Läkemedelsverket 1999;6:28–30.
   Google Scholar
• Dalgard O, Konopski Z, Bosse FJ, Nordstrand B, Sandvei P, Karlsen L, et al. Hepatitt C - utredning og behandling. Tidsskr Nor Laegeforen 2011;131:15.
   PubMedGoogle Scholar
• Niederau C, Huppe D, Zehnter E, Moller B, Heyne R, Christensen S, et al. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World J Gastroenterol 2012;18:1339–47.
   PubMed Web of Science ®Google Scholar
• Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005;20:754–8.
   PubMed Web of Science ®Google Scholar
• Delwaide J, El Saouda R, Gerard C, Belaiche J, Groupe Liegeois d'Etude des Virus H. Hepatitis C infection: eligibility for antiviral therapies. Eur J Gastroenterol Hepatol 2005;17:1185–9.
   PubMed Web of Science ®Google Scholar
• Lowry DJ, Ryan JD, Ullah N, Kelleher TB, Crowe J. Hepatitis C management: the challenge of dropout associated with male sex and injection drug use. Eur J Gastroenterol Hepatol 2011;23:32–40.
   PubMed Web of Science ®Google Scholar
• McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012;32:151–6.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007;46:1741–9.
   PubMedGoogle Scholar
• Gidding HF, Law MG, Amin J, Ostapowicz G, Weltman M, Macdonald GA, et al. Hepatitis C treatment outcomes in Australian clinics. Med J Aust 2012;196:633–7.
   PubMed Web of Science ®Google Scholar
• Bourliere M, Ouzan D, Rosenheim M, Doffoel M, Marcellin P, Pawlotsky JM, et al. Pegylated interferon-alpha2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007). Antivir Ther 2012;17:101–10.
   PubMed Web of Science ®Google Scholar
• Hydes T, Allen H, Al-Shamma S, Hovell C, Sharer NM, Williams EJ. District general hospital networks can provide safe and effective hepatitis C treatment: results of a 5-year audit. Eur J Gastroenterol Hepatol 2013; doi: 10.1097/MEG.0b013e32835fba14; PubMed PMID: 23510967.
   PubMedGoogle Scholar
• Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, et al. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur J Gastroenterol Hepatol 2012;24:646–55.
   PubMed Web of Science ®Google Scholar
• Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci 2011;56:2221–6.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580–93.
   PubMed Web of Science ®Google Scholar
• Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907–17.
   PubMed Web of Science ®Google Scholar